Penne Mara, Sarraf Yazdy Maryam, Nair Kruti Sheth, Cheson Bruce D
Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC.
Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC.
Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):637-644. doi: 10.1016/j.clml.2017.06.033. Epub 2017 Jun 30.
Bendamustine, typically in combination with rituximab, is an effective treatment for chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma. Despite its acceptable short-term toxicity profile, long-term toxicities are less well established. This study investigated the long-term adverse effects of bendamustine and responses to subsequent treatments.
Charts of 194 patients were retrospectively reviewed; 54% had received prior treatment (76% attained complete response [CR] or partial response [PR]).
Patients who did not achieve a CR or PR did not respond well to subsequent treatments. Malignancies following bendamustine were diagnosed in 11% (21) of patients (first line [7] and salvage [14]), including squamous (8) or basal cell (4) skin cancers; prostate cancer (3), renal cancer (3), bladder cancer (2), melanoma (2), lung cancer (1), and histiocytic sarcoma (1). There were no occurrences of therapy-related myelodysplastic syndrome or acute myelogenous leukemia reported. Infections occurred in 63% of patients; however, no deaths were attributable to bendamustine.
Bendamustine is an effective therapy with limited long-term sequelae in patients with lymphoid malignancies.
苯达莫司汀通常与利妥昔单抗联合使用，是治疗慢性淋巴细胞白血病（CLL）和B细胞非霍奇金淋巴瘤的有效方法。尽管其短期毒性可接受，但长期毒性尚不明确。本研究调查了苯达莫司汀的长期不良反应以及对后续治疗的反应。
回顾性分析了194例患者的病历；54%的患者曾接受过先前治疗（76%达到完全缓解[CR]或部分缓解[PR]）。
未达到CR或PR的患者对后续治疗反应不佳。11%（21例）的患者在使用苯达莫司汀后被诊断出患有恶性肿瘤（一线治疗[7例]和挽救性治疗[14例]），包括鳞状（8例）或基底细胞（4例）皮肤癌；前列腺癌（3例）、肾癌（3例）、膀胱癌（2例）、黑色素瘤（2例）、肺癌（1例）和组织细胞肉瘤（1例）。未报告发生与治疗相关的骨髓增生异常综合征或急性髓系白血病。63%的患者发生感染；然而，没有死亡病例归因于苯达莫司汀治疗。
苯达莫司汀是治疗淋巴系统恶性肿瘤患者的有效疗法，长期后遗症有限。
